IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population (EDISON)

This study is currently recruiting participants.
Verified April 2013 by Ipsen
Sponsor:
Information provided by (Responsible Party):
Ipsen
ClinicalTrials.gov Identifier:
NCT01676090
First received: August 22, 2012
Last updated: April 22, 2013
Last verified: April 2013
  Purpose

To determine the normative ranges of the Insulin-like Growth Factor 1 (IGF-1), Insulin-like growth factor-binding protein 3 (IGFBP-3), Acid-Labile Subunit (ALS) according to age, sex and pubertal stage of a healthy paediatric Spanish population.


Condition
IGF-1 Deficiency

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: An Epidemiologic, Descriptive and Cross-sectional Study of the IGF-1, IGFBP-3 and ALS Normative Ranges in a Healthy Paediatric Spanish Population, Divided Into Chronological Age, Sex and Pubertal Stage

Resource links provided by NLM:


Further study details as provided by Ipsen:

Primary Outcome Measures:
  • IGF-1 levels according to age, sex and pubertal stage in healthy paediatric volunteers [ Time Frame: At the time of participant's single study visit (day 1) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • IGFBP-3 levels according to age, sex and pubertal stage in healthy paediatric volunteers [ Time Frame: At the time of participant's single study visit (day 1) ] [ Designated as safety issue: No ]
  • ALS levels according to age, sex and pubertal stage in healthy paediatric volunteers [ Time Frame: At the time of participant's single study visit (day 1) ] [ Designated as safety issue: No ]

Estimated Enrollment: 1150
Study Start Date: July 2012
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Healthy paediatric Spanish population

Criteria

Inclusion Criteria:

  • Children of either sex of Caucasian parents
  • Age: newborns up to and including 18 years of age
  • Length/height, weight and body mass index (BMI) within the mean +/- 2SD (Standard Deviation) and in accordance with the growth charts of the 2010 Spanish cross-sectional growth study (Carrascosa Lezcano et al 2010)
  • Signed consent by at least one parent or legal guardian (if subject is ≤18 years) and by subject if ≥12 years

Exclusion Criteria:

  • Early or advanced puberty (pubertal signs: between 8 and 9 years old in girls, and between 9 and 10 years old in boys), or delayed puberty (no puberty onset in ≥ 13 year-old girls, and in ≥ 14 year-old boys)
  • Chronic diseases including, but not limited to, endocrinologic diseases, chromosomal diseases, chronic diseases of renal, hepatic and/or cardiac aetiology, and tumour processes
  • An acute disease during the last two weeks prior to recruitment
  • Any clinically significant out-of-range lab value
  • Healthy paediatric volunteers who are under medical treatment (contraception permitted)
  • A family history of short stature (either parent < P3)
  • Children born small for gestational age (birth weight, length, or head circumference < P10)
  • Adopted children or conceived through in vitro fertilization ( IVF )
  • Subjects who are unwilling or unable in the opinion of the investigator or sponsor to undergo all the study procedures
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01676090

Contacts
Contact: Ipsen Recruitment Enquiries clinical.trials@ipsen.com

Locations
Spain
Fundación Sant Joan de Deu Recruiting
Barcelona, Spain
Hospital Universitari Vall d´Hebron Recruiting
Barcelona, Spain
Hospital de Cruces Recruiting
Bilbao, Spain
Hospital Infantil Universitario Niño Jesús Not yet recruiting
Madrid, Spain
Hospital 12 de Octubre Not yet recruiting
Madrid, Spain
Hospital Universitario La Paz Recruiting
Madrid, Spain
Hospital Clínico Universitario de Santiago de Compostela Recruiting
Santiago de Compostela, Spain
Hospital Universitario Nuestra Señora de Valme Recruiting
Sevilla, Spain
Hospital Miguel Servet Recruiting
Zaragoza, Spain
Sponsors and Collaborators
Ipsen
Investigators
Study Director: Arturo Rojas De Filippis, MD Ipsen
  More Information

No publications provided

Responsible Party: Ipsen
ClinicalTrials.gov Identifier: NCT01676090     History of Changes
Other Study ID Numbers: A-92-52800-020
Study First Received: August 22, 2012
Last Updated: April 22, 2013
Health Authority: Spain: Agencia Española de Medicamentos y Productos Sanitarios

ClinicalTrials.gov processed this record on May 21, 2013